Dexamethasone and clinically significant postoperative nausea and vomiting: a prespecified substudy of the randomised perioperative administration of dexamethasone and infection (PADDI) trial

Br J Anaesth. 2022 Sep;129(3):327-335. doi: 10.1016/j.bja.2022.05.018. Epub 2022 Jul 6.

Abstract

Background: Clinically significant postoperative nausea and vomiting (PONV) is a patient-reported outcome which reflects patient experience. Although dexamethasone prevents PONV, it is unknown what impact it has on this experience.

Methods: In this prespecified embedded superiority substudy of the randomised Perioperative Administration of Dexamethasone and Infection (PADDI) trial, patients undergoing non-urgent noncardiac surgery received dexamethasone 8 mg or placebo intravenously after induction of anaesthesia, and completed a validated PONV questionnaire. The primary outcome was the incidence of clinically significant PONV on day 1 or day 2 postoperatively. Secondary outcomes included the incidence of clinically significant PONV and severe PONV on days 1 and 2 considered separately.

Results: A total of 1466 participants were included, with 733 patients allocated to the dexamethasone arm and 733 to matched placebo. The primary outcome occurred in 52 patients (7.1%) in the dexamethasone arm and 66 (9%) patients in the placebo arm (relative risk [RR]=0.79; 95% confidence interval [CI], 0.56-1.11; P=0.18). Severe PONV occurred on day 2 in 27 patients (3.9%) in the dexamethasone arm and 47 patients (6.7%) in the placebo arm (RR=0.58; 95% CI, 0.37-0.92; P=0.02; number needed-to-treat (NNT)=36.7; 95% CI, 20-202). In the entire cohort of 8880 PADDI patients, lower nausea scores, less frequent administration of antiemetics, and fewer vomiting events were recorded by patients in the dexamethasone arm up to day 2 after surgery.

Conclusions: Administration of dexamethasone 8 mg i.v. did not influence clinically significant PONV. Dexamethasone administration did, however, decrease the incidence and severity of PONV, and was associated with less frequent administration of antiemetic agents.

Clinical trial registration: ACTRN12614001226695.

Keywords: antiemetic; complication; dexamethasone; glucocorticoid; patient-centred outcome; postoperative nausea and vomiting.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Antiemetics* / adverse effects
  • Antiemetics* / therapeutic use
  • Dexamethasone
  • Double-Blind Method
  • Humans
  • Incidence
  • Postoperative Nausea and Vomiting* / chemically induced
  • Postoperative Nausea and Vomiting* / epidemiology
  • Postoperative Nausea and Vomiting* / prevention & control

Substances

  • Antiemetics
  • Dexamethasone